7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,556.48

+1,073.97

+1.40%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

Autonomix Medical, Inc. (AMIX)

1.8100 -0.2500 (-12.14%)

At close: October 30 at 4:00:00 PM EDT

2.0000 +0.1900 (+10.50%)

After hours: October 30 at 7:43:07 PM EDT

Loading Chart for AMIX

Chart Range Bar

Interval:

In partnership with ChartIQ

Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation

Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation

Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance

Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance

Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform

Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform

Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors

Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

Autonomix Medical Receives U.S. Patent for Precision Neuromodulation Platform Expansion

Autonomix Medical Receives U.S. Patent for Precision Neuromodulation Platform Expansion

Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy

Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy

Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform

Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform

Mobilize your Website

View Site in Mobile | Classic

Share by: